Prophylaxis with low-molecular-weight heparin reduces thrombotic events and allows continuation of asparaginase containing regimens during intensification phase.

Authors :: Sibai H
Atenafu EG
Seki JT
Source :: British journal of haematology [Br J Haematol] 2022 Apr; Vol. 197 (2), pp. e32-e34. Date of Electronic Publication: 2022 Jan 07.
Publication Year :: 2022

Subjects :: Anticoagulants therapeutic use
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight therapeutic use
Humans
Asparaginase adverse effects
Thrombosis drug therapy
Thrombosis prevention & control

Full Text Access

Tools